Increased CDRH Post-Approval Vigilance Plays Out In Medtronic X-Stop Trials
This article was originally published in The Gray Sheet
Executive Summary
Medtronic clinical executive Ruchir Sehra says CDRH's newfound rigor in the postmarket area is evident in its approach to the firm's post-approval study of the X-Stop spinal implant
You may also be interested in...
Analysis: Minimally Invasive Lower-Back Treatments Lack Good Data For Comparison
The scarcity of randomized data for device lower-back pain treatments limits comparisons of their clinical effectiveness and value, researchers conclude in a recent report.
Analysis: Minimally Invasive Lower-Back Treatments Lack Good Data For Comparison
The scarcity of randomized data for device lower-back pain treatments limits comparisons of their clinical effectiveness and value, researchers conclude in a recent report.
Medtronic Taps Into Expanded Spinal Market With $3.9 Billion Kyphon Deal
Medtronic is aiming to expand the breadth of its spinal offerings and, in particular, reach a relatively untapped older patient population with its $3.9 billion acquisition of Kyphon, announced July 27 (see chart: "1Medtronic-Kyphon Deal Basics")